Author

Shomron Ben-Horin 1

1 University of Tel Aviv, Sheba Medical Center,Tel-Hashomer,Israel

Development and validation of DICS ( DIverticular Clinical Score) for symptomatic uncomplicated diverticular disease in a prospective patients cohort

Adi Lahat, Shomron Ben-Horin

DEVELOPMENT OF A SUBCUTANEOUS FORMULATION OF CT-P13 (INFLIXIMAB): MAINTENANCE SUBCUTANEOUS ADMINISTRATION MAY ELICIT LOWER IMMUNOGENICITY COMPARED TO INTRAVENOUS TREATMENT

Shomron Ben-Horin, Walter Reinisch, Byong Duk Ye, Rene Westhovens, Dae Hyun Yoo, Sang Joon Lee, Sung Young Lee, Mi Rim Kim, Stefan Schreiber

DIFFUSION-WEIGHTED MAGNETIC RESONANCE ENTEROGRAPHY AND CAPSULE ENDOSCOPY ACTIVITY ‎INDICES FOR QUANTIFICATION OF SMALL BOWEL INFLAMMATION IN PATIENTS WITH ESTABLISHED CROHN’S ‎DISEASE. ‎

Uri Kopylov, Eyal Klang, Shomron Ben-Horin, Doron Yablecovitch, Adi Lahat, Tomer Greener, Sandra Neuman, Nina Levhar, Arkadi Beytelman, Noa Rozendorn, Abraham (Rami) Eliakim, Michal Marianne Amitai

Do characteristics at diagnosis predict disease outcome and complications?

Shomron Ben-Horin

EARLY VEDOLIZUMAB DRUG LEVELS AND INDUCTION SUCCESS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Bella Ungar, Uri Kopylov, Mattitiahu Waterman, Ola Haj-Natour, Miri Yavzori, Orit Picard, Ella Fudim, Yehuda Chowers, Abraham (Rami) Eliakim, Shomron Ben-Horin

EFFICACY AND SAFETY OF VEDOLIZUMAB FOR INDUCTION OF REMISSION IN INFLAMMATORY BOWEL DISEASE- THE ISRAELI EXPERIENCE.

Uri Kopylov, Yulia Ron, Irit Avni-Biron, Benjamin Koslovsky, Mattitiahu Waterman, Salech Daher, Bella Ungar, Henit Yanai, Nitsan Maharshak, Ofer Ben-Bassat, Lev Lichtenstein, Ariella Bar Gil Shitrit, Eran Israeli, Abraham (Rami) Eliakim, Yehuda Chowers, Shomron Ben-Horin, Iris Dotan

ENDOSCOPIC AND HISTOLOGIC FINDINGS CORRELATE WITH FREE INFLIXIMAB FOUND IN UNINFLAMED TISSUE IN IBD PATIENTS

Haggai Bar-Yoseph, Alexandra Blatt, Sigal Pressman, Shiran Gerassy, Bella Ungar, Shomron Ben-Horin, Yehuda Chowers

EVALUATION OF CLINICAL RELATIONSHIP BETWEEN FECAL CALPROTECTIN AND ENDOSCOPIC FINDINGS IN ULCERATIVE COLITIS PATIENTS TREATED WITH INFLIXIMAB (CT-P13) SUBCUTANEOUS AND INTRAVENOUS THERAPY: RESULTS FROM A MULTICENTER, RANDOMIZED, CONTROLLED PIVOTAL TRIAL

Walter Reinisch, Jaroslaw Leszczyszyn, Robert Dudkowiak, Adi Lahat, Beata Gawdis-Wojnarska, Aldis Pukitis, Marek Horynski, Katalin Farkas, Jaroslaw Kierkuś, Maciej Kowalski, Shomron Ben-Horin, Stefan Schreiber, Sang Joon Lee, Sung Hyun Kim, Jee Hye Suh, Yun Ah Kim, Se Ra Kim, Seul Gi Lee, Byong Duk Ye

EXPOSURE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) IN PATIENTS WITH ACTIVE CROHN'S DISEASE AND ULCERATIVE COLITIS: ANALYSIS FROM A MULTICENTER, RANDOMIZED CONTROLLED PIVOTAL TRIAL

Byong Duk Ye, Jaroslaw Leszczyszyn, Robert Dudkowiak, Adi Lahat, Beata Gawdis-Wojnarska, Aldis Pukitis, Marek Horynski, Katalin Farkas, Jaroslaw Kierkuś, Maciej Kowalski, Stefan Schreiber, Walter Reinisch, Sang Joon Lee, Sung Hyun Kim, Jee Hye Suh, Mi Rim Kim, Han Na Kim, Shomron Ben-Horin

IDENTIFICATION OF NEUTRALIZING ANTI-INFLIXIMAB ANTIBODIES

Roni Weisshof, Alexandra Blatt, Aviva Dahan, Shomron Ben-Horin, Yehuda Chowers

Item 11 - 20 / 61
1
2
3 4 5 6 7